Rodexo
Health Care

Third quarter sales beat forecasts as Ocrevus shines


The headquarters of Roche AG in Basel, Switzerland.

Gianluca Colla | Bloomberg | Getty Images

The headquarters of Roche AG in Basel, Switzerland.

Roche’s third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus,
the Swiss drugmaker said on Thursday.

Roche third-quarter sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter.



Source : CNBC

Related posts

Cancer screening is so important and this move is vital change in programme (From HeraldScotland)

Rodexo

Blood test can reveal cardiovascular disease risk

Rodexo

Questions raised over efficiency of NHS referral management centres

Rodexo

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.